Molecular imaging and fusion targeted biopsy of the prostate.
Clin Transl Imaging
; 5(1): 29-43, 2017 Feb.
Article
en En
| MEDLINE
| ID: mdl-28971090
ABSTRACT
PURPOSE:
This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate.METHODS:
Literature search was performed through the PubMed database using the keywords "prostate cancer", "MRI/ultrasound fusion", "molecular imaging", and "targeted biopsy". Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer.RESULTS:
Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease.CONCLUSION:
Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Screening_studies
Idioma:
En
Revista:
Clin Transl Imaging
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos